Investor
Every published round Dementia Australia took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Dementia Australia has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Dementia Australia, as distinct from the investments it has made.
Companies Dementia Australia has backed that another company then bought. An exit for the holding, not a deal Dementia Australia did.
Stories naming Dementia Australia. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Kinoxis completed a $6.75 million round with new backer MainSequence and won a $2.5 million government-funded CUREator+ grant for dementia and pain drug development; MainSequence's Elaine Stead joins the board.
Also Startup Daily·Startup Daily·Dealroom·This Week in Australian Startups·Dynamic Business
Melbourne dementia drug developer Kinoxis secured $6.75 million equity led by Main Sequence plus a $2.5 million Medical Research Future Fund grant via CUREator+, funding trials of its agitation and pain drug candidates.
Australian medtech Ceretas hit a milestone in its CUREator+ program, unlocking the final instalment of a government-funded grant; the piece also recaps its A$8 million IPO and ASX listing earlier in 2026.
Government-backed CUREator+ program awards non-dilutive funding to seven Australian companies developing dementia and cognitive decline therapeutics, devices and digital health tools.
CUREator+, backed by Brandon BioCatalyst, ANDHealth and Dementia Australia, launches second round offering non-dilutive funding to startups targeting dementia and cognitive decline.
The CUREator+ incubator, backed by government funds and industry partners, launches its initial grant round offering non-dilutive capital to startups developing dementia and cognitive decline solutions.